<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002175</url>
  </required_header>
  <id_info>
    <org_study_id>265A</org_study_id>
    <nct_id>NCT00002175</nct_id>
  </id_info>
  <brief_title>Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.</brief_title>
  <official_title>Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Honolulu Medical Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of dinitrochlorobenzene (DNCB) in patients with early HIV infection
      by monitoring immunologic parameters and serum HIV RNA. To facilitate the understanding of
      possible alterations in the immunological status of the HIV+ patient cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>46</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinitrochlorobenzene</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests.

        For HIV+ patients:

          -  Patients must fail to meet the AIDS-defining criteria.

          -  CD4 lymphocyte count between 200 - 500 cells/mm3.

        Exclusion Criteria

        Co-existing Condition:

        Excluded:

        Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites.

        Concurrent Medication:

        Excluded:

          -  Patients who are likely to commence antiretrovirals within the 6-month study period.

          -  Patients using other immunomodulator therapies or other alternative therapies.

          -  Patients likely to require chemotherapy during the course of the study.

        Concurrent Treatment:

        Excluded:

          -  Patients who are likely to require significant UV light exposure during the study
             period.

          -  Patients who are likely to require radiation therapy during the course of the study.

        Prior Medication:

        Excluded:

          -  Prior exposure to DNCB.

          -  Patients who have used antiretroviral medications within the previous 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Queen Emma Clinics / The Queen's Med Ctr</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Cohort Studies</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Administration, Cutaneous</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Dinitrobenzenes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

